血漿分画の世界市場規模、シェア、成長分析、製品別、方法別、用途別、最終用途別-産業予測、2024～2031年

血漿分画の世界市場規模は、2022年には約308億7,000万米ドルと評価され、2023年の334億3,000万米ドルから上昇し、予測期間（2024～2031年）のCAGRは8.3%で、2031年には632億7,000万米ドルに達すると予測されています。

回復期血漿は、COVID-19の大流行時に、医師がウイルス感染患者の初期治療として利用したため、需要が高まった。例えば、2021年6月のFrontiers誌の論文によると、回復期血漿は入院COVID-19患者の治療と疾患の進行抑制のために世界中で広く使用されました。回復期血漿の輸血が症状の改善とウイルスクリアランスに関連することが研究で示され、COVID-19患者の治療に血漿分画の必要性が当初急増しました。しかし、パンデミックが沈静化し、ウイルスに感染する人が少なくなるにつれて、分析された市場は本調査の予測期間中に安定した成長を遂げると予想されます。市場の拡大を後押ししている要因はいくつかあります。これには、さまざまな治療領域における免疫グロブリンの利用の増加、高齢者人口の拡大、希少疾患の罹患率の上昇、血漿採取施設の世界の普及などが含まれます。例えば、2022年10月のWHOの統計によると、世界の60歳以上の高齢者の割合は2050年までにほぼ3倍になると予測されており、高齢者人口のかなりの部分は低・中所得国に居住しています。さらに、先進的な血漿分画法や製品を市場に導入することを目的とした、製品の発売、提携、合併、買収など、主要な市場参入企業によるさまざまな取り組みが、市場拡大にプラスに寄与すると予想されます。例えば、2022年1月、Octapharmaは欧州連合（EU）におけるCutaquigの使用拡大認可を取得しました。皮下投与のヒト免疫グロブリン製剤であるCutaquigは、遺伝性免疫不全の多くの患者に柔軟な治療選択肢を記載しています。全体として、高齢者人口の増加が予測され、希少疾患の有病率の増加、血漿採取センターの普及、主要市場参入企業による様々な取り組みが、予測期間中の市場成長にプラスの影響を与えると予想されます。しかし、業界は、血漿タンパク質製品の処理を管理する厳しい規制、高価格、償還の課題などの制約に直面しています。

目次

エグゼクティブサマリー

• 市場概要
• 隆盛と衰退

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模の推定
• 市場の危機と限界

親市場の分析

• 市場概要
• 市場規模
• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主要市場の考察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料の分析
• イノベーションマトリクス
• パイプライン製品の分析
• マクロ経済指標
• 主要投資の分析
• 主要成功要因
• 競合の程度

市場力学と展望

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• 規制情勢
• ポーターの分析
• 将来の混乱についての特別な考察

血漿分画の世界市場：製品別

• 市場概要
• アルブミン
• 免疫グロブリン
• 凝固因子
• プロテアーゼ阻害剤

血漿分画の世界市場：方法別

• 市場概要
• 遠心分離
• 深層濾過
• クロマトグラフィー

血漿分画の世界市場：用途別

• 市場概要
• 神経学
• 血液学
• 腫瘍学
• 免疫学
• 呼吸器学

血漿分画の世界市場：最終用途別

• 市場概要
• 病院・クリニック
• 臨床調査その他

血漿分画の世界市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • その他の欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2021年）
• 主要市場企業が採用した戦略
• 主要成功戦略
• 市場における最近の活動
• 主要企業の市場シェア（2021年）

主要企業プロファイル

• CSL Behring
• Grifols
• Octapharma
• Baxalta/Shire
• Kedrion
• China Biologic Products Holdings
• Sanquin
• Bio Products Laboratory
• Japan Blood Products Organization
• LFB Group
• Shanghai RAAS Blood Products
• Green Cross Corporation
• Baxter International Inc.
• Takeda Pharmaceutical Company Limited
• Beijing Tiantan Biological Products
• Biotest AG
• China National Pharmaceutical Group Co.（Sinopharm）
• GC Pharma
• ADMA Biologics
• Emergent BioSolutions

Global plasma fractionation market size was valued at around 30.87 billion in 2022 and is expected to rise from USD 33.43 billion in 2023 to reach a value of USD 63.27 billion by 2031, at a CAGR of 8.3 % over the forecast period (2024-2031).

Convalescent plasma witnessed heightened demand during the COVID-19 pandemic as doctors utilized it as an initial treatment for virus-infected patients. For example, according to a June 2021 Frontiers paper, convalescent plasma was extensively employed worldwide to treat hospitalized COVID-19 patients and mitigate disease progression. Studies have indicated that convalescent plasma transfusion is associated with improved symptomatology and virus clearance, leading to an initial surge in the need for plasma fractions to treat COVID-19 patients. However, as the pandemic waned and fewer individuals contracted the virus, the analyzed market is expected to witness steady growth over the study's forecast period. Several specific factors are fueling the expansion of the market. These include the increasing utilization of immunoglobulins across various therapeutic domains, the expanding elderly population, coupled with the rising incidence of rare diseases, and the proliferation of plasma collection facilities globally. For instance, according to WHO statistics from October 2022, the proportion of individuals worldwide aged over 60 is projected to nearly triple by 2050, with a significant portion of the elderly population residing in low- and middle-income countries. Furthermore, various initiatives undertaken by major market players, including product launches, partnerships, mergers, and acquisitions, aimed at introducing advanced plasma fractionation methods and products to the market, are expected to contribute positively to market expansion. For instance, in January 2022, Octapharma received authorization to expand the use of Cutaquig in the European Union (EU). Cutaquig, a subcutaneously administered human immunoglobulin, offers flexible therapeutic options for numerous patients with inherited immune deficiencies. Overall, the projected rise in the elderly population, coupled with an increase in the prevalence of rare diseases, the proliferation of plasma collection centers, and various initiatives by major market players, are all anticipated to positively impact market growth during the forecast period. However, the industry faces constraints such as stringent regulations governing the processing of plasma protein products, high pricing, and reimbursement challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the global plasma fractionation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Fractionation Market Segmental Analysis

The global plasma fractionation market is segmented based on product, method, application, end use, and region. By product, the market is segmented into albumin, immunoglobulins, coagulation factors, protease inhibitors. By method, the market is segmented into centrifugation, depth filtration, and chromatography. By application, the market is segmented into neurology, hematology, oncology, immunology, and pulmonology. By end use, the market is segmented into hospitals & clinics, clinical research, and others. By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Plasma Fractionation Market

The aging population significantly drives the plasma fractionation market. As individuals age, they become more susceptible to chronic illnesses and necessitate medical interventions, which often include plasma-derived products. This growing demographic of elderly individuals contributes to the increasing demand for plasma fractionation products as healthcare providers seek to address the healthcare needs associated with aging populations.

Restraints in the Global Plasma Fractionation Market

The high cost of plasma fractionation products poses a significant restraint on market growth. Manufacturing these products involves substantial expenses, rendering them unaffordable for certain patients and healthcare systems. This cost barrier limits access to these crucial treatments and hampers the overall growth potential of the market.

Market Trends of the Global Plasma Fractionation Market

Immunoglobulins serve as the primary treatment for various immunologic, hematologic, and neurologic conditions. Technological advancements in the past decade have led to increased diagnoses of immunological disorders. Consequently, there is a growing clinical demand for immunoglobulins, driven by the expanding genetic research aimed at defining and diagnosing immunodeficiency disorders. According to IG Living, a publication for the immune globulin (IG) community, immunoglobulins are utilized for numerous on- and off-label indications, with off-label uses comprising a significant portion, ranging from 20% to 60%, of their clinical application. Notably, the use of immunoglobulins for off-label purposes has surpassed their on-label applications in recent years. Furthermore, the prevalence of rare and autoimmune diseases, coupled with increased global research in immunology, is propelling the market's growth. According to the National Center for Advancing Translational Sciences, only a fraction of the 7,000 to 10,000 rare diseases identified have any form of treatment, indicating a vast unmet medical need. The surge in the incidence of rare disorders is contributing to the expansion of the immunoglobulin market, as these conditions necessitate ongoing treatment and management with immunoglobulin therapy.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Plasma Fractionation Market by Product

• Market Overview
• Albumin
• Immunoglobulins
• Coagulation Factors
• and Protease Inhibitors

Global Plasma Fractionation Market by Method

• Market Overview
• Centrifugation
• Depth Filtration
• and Chromatography

Global Plasma Fractionation Market by Application

• Market Overview
• Neurology
• Hematology
• Oncology
• Immunology
• and Pulmonology

Global Plasma Fractionation Market by End Use

• Market Overview
• Hospitals & Clinics
• Clinical Research and Others

Global Plasma Fractionation Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxalta/Shire
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Japan Blood Products Organization
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Tiantan Biological Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China National Pharmaceutical Group Co. (Sinopharm)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments